title: [Primary and secondary prevention of sudden cardiac death in the ICD Registry-Latin America].
abstract: OBJECTIVE
  The ICD Registry is an observational study conducted in Latin America to collect data on indications and follow-up care for primary or secondary prevention of sudden cardiac death patients. The objective of this study is to compare and evaluate the characteristics of primary versus secondary prevention in the patient population enrolled in the registry.
  
  
  METHODS
  Demographic data, indication, etiology, NYHA functional class and left ventricular ejection fraction (LVEF), pharmacological treatment at implant and the type of ICD implanted were also collected. During the follow-up period the ICD therapies delivered, patient hospitalizations and mortality were evaluated.
  
  
  RESULTS
  507 patients were evaluated. Average age 60 +/- 14 years old, 78% male. Coronary heart disease was the most common etiology (43.6%). NYHA Functional Class I/II at the time of implant (73.6%). Average LVEF was 34 +/- 16%. Out of 507 patients, 189 received an ICD for primary prevention; 318 for secondary prevention. Primary prevention patients were older, predominantly male and had a lower EF. The rate of mortality and hospitalizations were similar between both groups with a higher rate of appropriate therapies in secondary prevention patients.
  
  
  CONCLUSIONS
  This is the first study to demonstrate clinical characteristics of primary prevention patients in Latin America. There were no significant statistically differences in a short follow-up period in mortality or hospitalization as compared to the secondary prevention patient population in the Registry.
authors.affiliation: Hospital Italiano, Rosario, Argentina. jlramos@ciudad.com.ar
authors.forename: Jose L
authors.initials: JL
authors.lastname: Ramos
authors.forename: Claudio
authors.initials: C
authors.lastname: Muratore
authors.forename: José C
authors.initials: JC
authors.lastname: Pachón Mateos
authors.forename: Angel
authors.initials: A
authors.lastname: Rodríguez
authors.forename: Antonio
authors.initials: A
authors.lastname: González Hermosillo
authors.forename: René
authors.initials: R
authors.lastname: Asenjo
authors.forename: Diego
authors.initials: D
authors.lastname: Rodríguez
authors.forename: Silas
authors.initials: S
authors.lastname: Galvao
authors.forename: Mauricio
authors.initials: M
authors.lastname: Duque
authors.forename: Jaime
authors.initials: J
authors.lastname: Escudero
authors.forename: Walter
authors.initials: W
authors.lastname: Reyes Caorsi
authors.forename: Erick
authors.initials: E
authors.lastname: Cuvillier
authors.forename: Jennifer
authors.initials: J
authors.lastname: Maloney
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D016757:Death, Sudden, Cardiac / Q000453:epidemiology / Q000517:prevention & control*; D017147:Defibrillators, Implantable / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D007843:Latin America / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012042:Registries; D013318:Stroke Volume / Q000502:physiology
chemical_list: D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors